Abemaciclib

Marc Goodman of UBS lowered his EPS estimates for Eli Lilly and Co (NYSE: LLY) after the company announced that its Alzheimer's drug solanezumab failed to slow the cognitive decline in patients. Goodman, who previously had modeled about $1.1 billion for 2020 solanezumab sales, has cut 2016 EPS...

Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies. For Eli Lilly and Co (NYSE: LLY), ASCO will be...